Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells

Tyrosine kinase inhibitors (TKIs) are currently the first-line treatment for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. These patients receive platinum-based chemotherapy as the second-line treatment after they develop resistance to TKIs. Many...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, An-Fu, Chen, Man-Chin, Chen, Chao-Ju, Yang, Chih-Jen, Huang, Ming-Shyang, Liu, Yu-Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500319/
https://www.ncbi.nlm.nih.gov/pubmed/28683123
http://dx.doi.org/10.1371/journal.pone.0180383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500319/
https://www.ncbi.nlm.nih.gov/pubmed/28683123
http://dx.doi.org/10.1371/journal.pone.0180383

Ejemplares similares